Argus Research Maintains Buy on Amgen, Raises Price Target to $280
Portfolio Pulse from Benzinga Newsdesk
Argus Research analyst David Toung maintains a 'Buy' rating on Amgen (NASDAQ:AMGN) and raises the price target from $260 to $280.
September 18, 2023 | 5:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amgen's price target has been raised from $260 to $280 by Argus Research, maintaining a 'Buy' rating.
The raised price target indicates the analyst's increased confidence in the company's performance. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100